Kyverna Therapeutics (NASDAQ:KYTX) Reaches New 1-Year Low at $21.13

Kyverna Therapeutics, Inc. (NASDAQ:KYTX)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $21.13 and last traded at $21.30, with a volume of 24716 shares changing hands. The stock had previously closed at $22.43.

Analyst Ratings Changes

KYTX has been the topic of a number of recent analyst reports. SVB Leerink initiated coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They set an “outperform” rating and a $48.00 price target on the stock. Morgan Stanley initiated coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They set an “overweight” rating and a $40.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Kyverna Therapeutics in a report on Monday, March 4th. Wells Fargo & Company started coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an “overweight” rating and a $44.00 price objective on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an “overweight” rating and a $39.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $42.75.

Kyverna Therapeutics Trading Down 7.0 %

The business’s 50-day moving average is $26.33.

Insiders Place Their Bets

In other Kyverna Therapeutics news, major shareholder Northpond Ventures Iii Gp, Llc purchased 450,000 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were acquired at an average cost of $22.00 per share, for a total transaction of $9,900,000.00. Following the completion of the transaction, the insider now owns 450,000 shares of the company’s stock, valued at $9,900,000. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.